Opinion|Videos|July 18, 2024
NCCN Guidelines Revisions and ASCO 2024 Research Outlook
An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.
Advertisement
Episodes in this series
- How do you think the revised NCCN Guidelines for breast cancer will impact patient outcomes?
- What data, results, or insights are you looking forward to coming out of ASCO 2024?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Novel CLL Therapies Prompt New Treatment Considerations
2
Congress Unveils Massive Funding Bill to Avert Shutdown
3
Early Data Show Feasibility of in Vivo CAR T Therapy in Multiple Myeloma
4
Anlotinib Plus Chemotherapy Shows Promising Results in Advanced Soft Tissue Sarcoma
5
